66 related articles for article (PubMed ID: 33815976)
1. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
Lai S; Petramala L; Mastroluca D; Petraglia E; Di Gaeta A; Indino E; Panebianco V; Ciccariello M; Shahabadi HH; Galani A; Letizia C; D'Angelo AR
Medicine (Baltimore); 2016 Jul; 95(29):e4175. PubMed ID: 27442639
[TBL] [Abstract][Full Text] [Related]
2. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Sioulis A; Balaskas E; Zebekakis P; Sarafidis PA
Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429
[TBL] [Abstract][Full Text] [Related]
3. Serum endocan, asymmetric dimethylarginine and lipid profile in children with familial Mediterranean fever.
El Zayat RS; Hassan FM; Aboelkhair NT; Abdelhakeem WF; Abo Hola AS
Pediatr Res; 2024 Feb; ():. PubMed ID: 38396131
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Serum Endocan Levels and Other Predictors of Endothelial Dysfunction in Obese Women.
Mercantepe F; Baydur Sahin S; Cumhur Cure M; Karadag Z
Angiology; 2023; 74(10):948-957. PubMed ID: 36369649
[TBL] [Abstract][Full Text] [Related]
5. Relationship between asymmetric dimethylarginine and endothelial dysfunction in patients with rheumatoid arthritis.
Şentürk T; Yılmaz N; Sargın G; Köseoğlu K; Yenisey Ç
Eur J Rheumatol; 2016 Sep; 3(3):106-108. PubMed ID: 27733940
[TBL] [Abstract][Full Text] [Related]
6. The Role of the L-Arginine-Nitric Oxide Molecular Pathway in Autosomal Dominant Polycystic Kidney Disease.
Ene CD; Penescu M; Nicolae I; Capusa C
J Pers Med; 2024 Mar; 14(3):. PubMed ID: 38541041
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Manifestations and Management in ADPKD.
Sagar PS; Rangan GK
Kidney Int Rep; 2023 Oct; 8(10):1924-1940. PubMed ID: 37850017
[TBL] [Abstract][Full Text] [Related]
8. The Relationship Between Endocan and Serum Inflammatory Markers in Patients with Senile Calcific Aortic Stenosis.
Akgün DE; Avcı E; Yaman A; Şafak Ö; Kısacık HL; Argan O; Yıldırım SE; Yıldırım T; Naser A; Gençbay M; Kırış T
Anatol J Cardiol; 2024 Jan; 28(2):102-8. PubMed ID: 38168010
[TBL] [Abstract][Full Text] [Related]
9. The relation of serum endocan and soluble endoglin levels with metabolic control in children and adolescents with type 1 diabetes mellitus.
Anık A; Çelik E; Çevik Ö; Ünüvar T; Anık A
J Pediatr Endocrinol Metab; 2020 Jul; ():. PubMed ID: 32697760
[TBL] [Abstract][Full Text] [Related]
10. Endocan and Endothelial Dysfunction in Obese Women.
Madani K; Ozbay HS; Ahmed F; Ozbay MB
Angiology; 2024 Feb; ():33197241233054. PubMed ID: 38349222
[No Abstract] [Full Text] [Related]
11. Semantic Instance Segmentation of Kidney Cysts in MR Images: A Fully Automated 3D Approach Developed Through Active Learning.
Gregory AV; Anaam DA; Vercnocke AJ; Edwards ME; Torres VE; Harris PC; Erickson BJ; Kline TL
J Digit Imaging; 2021 Aug; 34(4):773-787. PubMed ID: 33821360
[TBL] [Abstract][Full Text] [Related]
12. Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions.
Kim J; Lee J
Ann Pediatr Endocrinol Metab; 2021 Mar; 26(1):1-13. PubMed ID: 33819954
[TBL] [Abstract][Full Text] [Related]
13. Exploring Adiponectin in Autosomal Dominant Kidney Disease: Insight and Implications.
Nigro E; Mallardo M; Amicone M; D'Arco D; Riccio E; Marra M; Pasanisi F; Pisani A; Daniele A
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674417
[TBL] [Abstract][Full Text] [Related]
14. How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension?
Hirooka Y
Hypertens Res; 2024 Mar; 47(3):794-795. PubMed ID: 38114652
[No Abstract] [Full Text] [Related]
15. Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis.
Behnoush AH; Khalaji A; Bahiraie P; Alehossein P; Shobeiri P; Peisepar M; Cannavo A
Hypertens Res; 2023 Oct; 46(10):2388-2399. PubMed ID: 37580451
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and Diagnostic Value of Endocan in Kidney Diseases.
Samouilidou E; Athanasiadou V; Grapsa E
Int J Nephrol; 2022; 2022():3861092. PubMed ID: 35321346
[TBL] [Abstract][Full Text] [Related]
17. Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease.
Ekinci İ; Buyukkaba M; Cinar A; Tunc M; Cebeci E; Gursu M; Kazancioglu R
Cureus; 2021 Feb; 13(2):e13561. PubMed ID: 33815976
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation.
Ozalper V; Kara M; Tanoglu A; Cetındaglı I; Ozturker C; Hancerlı Y; Hıra S; Kara K; Beyazıt Y; Yazgan Y
Clin Rheumatol; 2017 Sep; 36(9):2071-2077. PubMed ID: 28074304
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
